@article{Tade2024, 
author = {Rahul S. Tade and Swapnil N. Jain and Janhavi T. Satyavijay and Pratham N. Shah and Tejaswi D. Bari and Tanushri M. Patil and Ruhi P. Shah},
title = {Artificial Intelligence in the Paradigm Shift of Pharmaceutical Sciences: A Review},
year = {2024},
journal = {Nano Biomedicine and Engineering},
volume = {16},
number = {1},
pages = {64-77},
keywords = {artificial intelligence (AI), pharmaceutical research, drug discovery, academic research, precision medicine, job market},
url = {https://www.sciopen.com/article/10.26599/NBE.2023.9290043},
doi = {10.26599/NBE.2023.9290043},
abstract = {AI has emerged as a revolutionary technology in the pharmaceutical and biomedical fields. This review explores its transformative role, particularly in drug development, the discovery of future interventions in the pharmaceutical sector. By leveraging AI, these processes have become more efficient, cost-effective, and capable of delivering personalized medicine to individual patients. Moreover, AI’s potential in disease prevention and outbreak prediction is promising, as it can analyze vast datasets to identify crucial patterns and trends, leading to targeted interventions for combating diseases. In biomedical research, AI has proven highly beneficial, especially in genomics, proteomics, and metabolomics, where it enables researchers to comprehensively analyze complex biological data, uncovering new insights and accelerating scientific discoveries. The impact of AI is also evident in the patient-physician interface, as it enhances diagnostic accuracy and treatment efficiency, ultimately improving patient care.}
}